[go: up one dir, main page]

SV2004001426A - Combinacion farmaceutica ref.pcs22049 - Google Patents

Combinacion farmaceutica ref.pcs22049

Info

Publication number
SV2004001426A
SV2004001426A SV2002001426A SV2002001426A SV2004001426A SV 2004001426 A SV2004001426 A SV 2004001426A SV 2002001426 A SV2002001426 A SV 2002001426A SV 2002001426 A SV2002001426 A SV 2002001426A SV 2004001426 A SV2004001426 A SV 2004001426A
Authority
SV
El Salvador
Prior art keywords
pcs22049
pharmaceutical combination
ref
combination ref
receiver agonist
Prior art date
Application number
SV2002001426A
Other languages
English (en)
Inventor
Michael Yeadon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SV2004001426A publication Critical patent/SV2004001426A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMBINACION QUE COMPRENDE (A) UN AGONISTA DEL RECEPTOR DE ADENOSINA A2A COMO SE DEFINE EN LA PRESENTE MEMORIA Y (B) UN AGONISTA DEL RECEPTOR B2-ADRENERGICO, PARA LA ADMINISTRACION SIMULTANEA, SECUENCIAL O POR SEPARADO POR VIA INHALADA EN EL TRATAMIENTO DE UNA ENFERMEDAD OBSTRUCTIVA DE LAS VIAS RESPIRATORIAS U OTRA ENFERMEDAD INFLAMATORIA
SV2002001426A 2001-12-06 2002-12-05 Combinacion farmaceutica ref.pcs22049 SV2004001426A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0129270.5A GB0129270D0 (en) 2001-12-06 2001-12-06 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
SV2004001426A true SV2004001426A (es) 2004-05-07

Family

ID=9927164

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2002001426A SV2004001426A (es) 2001-12-06 2002-12-05 Combinacion farmaceutica ref.pcs22049

Country Status (37)

Country Link
EP (1) EP1455799B1 (es)
JP (1) JP2005513041A (es)
KR (1) KR100685557B1 (es)
CN (1) CN1856314A (es)
AP (2) AP2004003082A0 (es)
AR (1) AR037634A1 (es)
AT (1) ATE293982T1 (es)
AU (1) AU2002351066B2 (es)
BR (1) BR0214998A (es)
CA (1) CA2469085A1 (es)
CO (1) CO5580752A2 (es)
DE (1) DE60203934T2 (es)
DK (1) DK1455799T3 (es)
EA (1) EA200400639A1 (es)
EC (1) ECSP045132A (es)
ES (1) ES2239728T3 (es)
GB (1) GB0129270D0 (es)
GT (1) GT200200258A (es)
HN (1) HN2002000348A (es)
HR (1) HRP20040517A2 (es)
HU (1) HUP0402540A3 (es)
IS (1) IS7280A (es)
MA (1) MA27150A1 (es)
MX (1) MXPA04005506A (es)
NO (1) NO20042839L (es)
NZ (1) NZ533054A (es)
OA (1) OA12738A (es)
PA (1) PA8560701A1 (es)
PE (1) PE20030834A1 (es)
PL (1) PL370739A1 (es)
PT (1) PT1455799E (es)
SV (1) SV2004001426A (es)
TN (1) TNSN04101A1 (es)
TW (1) TWI256388B (es)
UY (1) UY27566A1 (es)
WO (1) WO2003047598A1 (es)
ZA (1) ZA200403966B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100785969B1 (ko) * 2004-05-12 2007-12-14 동아제약주식회사 Ｆｇｆ2를 유효성분으로 포함하는 천식 및 만성폐쇄성폐질환 예방 또는 치료제
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
CN115919780A (zh) 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
JPWO2022050230A1 (es) * 2020-09-03 2022-03-10

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives

Also Published As

Publication number Publication date
AR037634A1 (es) 2004-11-17
TNSN04101A1 (fr) 2006-06-01
AP2004003053A0 (en) 2004-06-30
ATE293982T1 (de) 2005-05-15
IS7280A (is) 2004-05-21
EA200400639A1 (ru) 2004-12-30
CN1856314A (zh) 2006-11-01
NO20042839L (no) 2004-07-05
ES2239728T3 (es) 2005-10-01
CO5580752A2 (es) 2005-11-30
KR20050044697A (ko) 2005-05-12
JP2005513041A (ja) 2005-05-12
TW200300759A (en) 2003-06-16
AP2004003082A0 (en) 2004-09-30
PL370739A1 (en) 2005-05-30
HN2002000348A (es) 2005-02-04
UY27566A1 (es) 2003-07-31
TWI256388B (en) 2006-06-11
EP1455799A1 (en) 2004-09-15
HUP0402540A2 (hu) 2005-07-28
DK1455799T3 (da) 2005-06-27
WO2003047598A1 (en) 2003-06-12
MXPA04005506A (es) 2004-12-10
GT200200258A (es) 2003-08-22
PA8560701A1 (es) 2004-05-07
AU2002351066B2 (en) 2007-10-18
HUP0402540A3 (en) 2008-04-28
PT1455799E (pt) 2005-08-31
HRP20040517A2 (en) 2004-10-31
PE20030834A1 (es) 2003-10-08
ECSP045132A (es) 2004-07-23
EP1455799B1 (en) 2005-04-27
BR0214998A (pt) 2004-12-28
KR100685557B1 (ko) 2007-02-22
OA12738A (en) 2006-06-29
MA27150A1 (fr) 2005-01-03
DE60203934D1 (de) 2005-06-02
AU2002351066A1 (en) 2003-06-17
GB0129270D0 (en) 2002-01-23
DE60203934T2 (de) 2006-02-23
CA2469085A1 (en) 2003-06-12
ZA200403966B (en) 2005-06-22
NZ533054A (en) 2007-02-23

Similar Documents

Publication Publication Date Title
PA8546101A1 (es) Un antagonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas
CL2008002207A1 (es) Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04).
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
GB0008269D0 (en) Combination chemotherapy
MXPA03008955A (es) Agente terapeutico para enfermedades de tipo artritides cronicas o enfermedades relacionadas con la ninez.
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
CR11341A (es) Combinacion que comprende derivados de purina y otros compuestos y el uso de los mismos para el tratamiento de enfermedades de vias respiratorias inflamatorias y obstructivas
CR7152A (es) Un inhibidor de pde4 y un agente de anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
TW200642704A (en) Oral drug delivery system and methods of use thereof
SV2004001426A (es) Combinacion farmaceutica ref.pcs22049
PA8560401A1 (es) Combinacion farmaceutica
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
PA8560601A1 (es) Combinacion farmaceutica
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
NO20043314L (no) Sedative non-benzodiazepinformuleringer
DOP2002000514A (es) Combinacion farmaceutica.
DOP2002000523A (es) Combinacion farmaceutica.
CR7162A (es) Un agonista de a2a en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas
UY27308A1 (es) Un agonista de a2a en combinación con un agente anticolinérgico para el tratamiento de enfermedades obstructivas de las vias aéreas
HN2002000045A (es) Uso de agonistas inversos da gaba en combinacion con agonistas parciales del receptor de nicotina, estrogenos, moduladores selectivos de estrogenos o vitamina e, para el tratamiento de transtornos cognitivos.
HN2002000128A (es) Un agonista de a2a en combinación con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas.
AR046259A1 (es) Composicion farmaceutica que comprende un antagonista de los receptores a2a de adenosina
ECSP003350A (es) Combinaciones de un agonista de beta- 2- y un esteroide

Legal Events

Date Code Title Description
FD Lapse